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Malaria remains a major cause for morbidity and mortality worldwide, predominantly in infants and 
young children in sub-Saharan Africa. To this end, anti-malarial drugs play the main role in the 
elimination of erythrocytic stages of malaria parasites. However, drug resistance has already developed 
to all the antimalarial drug classes with one notable exception, the artemisinin (1). Therefore, an 
effective pre-erythrocytic malaria vaccine is urgently required. Plasmodium falciparum 
circumsporozoite protein (PfCSP) is the main target antigen in development of pre-erythrocytic 
malaria vaccines. PfCSP mainly consists of three regions: The N-terminus, repeat, and the C-terminus.  
PfCSP plays a fundamental role in parasite development as well as the infection and is a molecular 
target of protective antibodies. However, the mechanism of PfCSP induced protective immune 
response has not been clarified in details. Therefore, it is necessary to identify the effective region 
induced by PfCSP-based vaccination. Moreover, to evaluate PfCSP vaccines in animal models, 
challenge by intravenous sporozoite injection is preferentially used. However, in clinical trials, 
vaccinated human volunteers are exposed to the bites of malaria-infected mosquitoes. Therefore, the 
overall aim of this thesis was to down-select Plasmodium falciparum circumsporozoite protein 
(PfCSP)-in-adjuvant vaccines formulation by comparing their protective efficacy in mice using two 
different challenge models. Concurrently, we assessed whether the immune responses induced by 
truncated PfCSP vaccines are as important as those induced by full-length PfCSP (PfCSP-F) in the 
protection.  
In this study, we down-selected Escherichia coli-produced full-length PfCSP (PfCSP-F), and its 
three truncated PfCSPs based on their abilities to elicit immune response and protection in mice against 
two challenge models. We showed that immunization with three-dose of PfCSP-F elicited high PfCSP-
specific antibody titers and 100% protection against the bites of infected mosquitoes. Meanwhile, 
three-dose truncated PfCSP induced 60%–70% protection after immunization with each truncated 
PfCSP. Heterologous prime-boost immunization regimen with adenovirus–PfCSP–F and R32LR 
greatly induced complete protection against intravenous sporozoite injection. These results suggest 
that the complete elimination of sporozoites in the skin injected by the bites of infected mosquitoes 
requires humoral responses against each region induced by PfCSP-F, whereas induction of fast-acting 
humoral responses to repeat region plays an important role against intravenous sporozoite injection 
when adenovirus-PfCSP-F was used as a priming vaccine. Thus, the protective efficacy of CSP-based 









は、CSPの N末を除く中央部 NANP繰り返しから C末を含む部分を B型肝炎表面抗原と
結合させた融合タンパクにAS01Eアジュバントを添加したサブユニットワクチンであるが、
アフリカで行われた乳児を対象とした第 III 相臨床試験での有効率は 30% に満たない非常
に限定的なものであった。本論文は CSPを全長および 3つの領域（N末、中央部NANP繰
り返し、C末）に分けて大腸菌で発現・精製し、各種アジュバントと一緒にマウスに接種し、
抗体価および感染防御効果を検討した。アジュバントは Imject Alumが最も抗 CSP抗体価
を誘導し、全長 CSP との組み合わせでは蚊による吸血チャレンジで 100%の完全な感染防
御効果を達成した。RTS,Sには存在しない N末配列を含む全長が感染防御免疫には重要で
あることを示したことは今後のマラリアワクチン開発に大きなヒントとなる。本審査委員会
は、研究成果の新規性および口頭発表会における学位申請者の発表と討論の能力を考慮して、
当該学位論文は博士（学術）に値すると判定した。 
 
 
